Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review

References

• López-Fernández T, Martín-García A, Roldán Rabadán I, et al. Abordaje de la fibrilación auricular en pacientes con cáncer activo. Documento de consenso de expertos y recomendaciones. Rev Esp Cardiol. 2019;72(9):749–759. doi:10.1016/j.recesp.2019.03.017
   PubMed Web of Science ®Google Scholar
• Morillo CA, Banerjee A, Perel P, et al. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017;14(3):195–203. doi:10.11909/j.1671-5411.2017.03.011
   PubMedGoogle Scholar
• Bordignon S, Chiara Corti M, Bilato C. Atrial fibrillation associated with heart failure, stroke and mortality. J Atr Fibrillation. 2012;5(1):467.
   PubMedGoogle Scholar
• Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv41–iv50.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33. doi:10.1016/j.annonc.2020.09.019
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298–308. doi:10.1016/j.annonc.2020.11.008
   PubMed Web of Science ®Google Scholar
• Baptiste F, Cautela J, Ancedy Y, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6(1):e001049. DOI:10.1136/openhrt-2019-001049
   PubMed Web of Science ®Google Scholar
• Tang CPS, McMullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2018;59(7):1554–1564. doi:10.1080/10428194.2017.1375110.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–1307.
   PubMed Web of Science ®Google Scholar
• Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56–63. doi:10.1016/j.critrevonc.2019.02.001.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Lévy V, Tam CS, et al., Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3): 462–466. doi:10.1111/bjh.14324.
   PubMed Web of Science ®Google Scholar
• Thorp BC, Badoux X. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leuk Lymphoma. 2018;59(2):311–320.
   PubMed Web of Science ®Google Scholar
• Martín García A, Mitroi C, Mazón Ramos P, et al. Estratificación, monitorización y control del riesgo cardiovascular en pacientes con cáncer. Documento de consenso de SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC y AECC. Rev Esp Cardiol. 2021;74:438–448.
   PubMedGoogle Scholar
• Boriani G, Corradini P, Cuneo A, et al. Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol. 2018;36(4):624–632. doi:10.1002/hon.2503
   PubMed Web of Science ®Google Scholar
• Iskierka-Jażdżewska E, Robak T. Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13(1):39–53.
   PubMed Web of Science ®Google Scholar
• Swarup S, Sultan A, Tijani L, et al. Updated meta-analysis to evaluate the incidence of atrial fibrillation and major bleeding in patients with hematologic malignancies treated with ibrutinib. Blood. 2019;134(Supplement_1):2200. doi:10.1182/blood-2019-123261
   Google Scholar
• Brown JR, Moslehi J, O’Brien S, et al., Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10): 1796–1805. doi:10.3324/haematol.2017.171041.
   PubMed Web of Science ®Google Scholar
• Stühlinger MC, Weltermann A, Staber P, et al. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wien Klin Wochenschr. 2020;132(3–4):97–109. doi:10.1007/s00508-019-1534-1
   PubMed Web of Science ®Google Scholar
• Pellegrini L, Novak U, Andres M, et al. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103238.
   PubMed Web of Science ®Google Scholar
• Escalada González L, de Ugarriza P L, Fernández Rodríguez M, et al. Evaluation of adverse effects of ibrutinib: experience from a northern hospital of Spain . EHA. 2021.
   Google Scholar
• Molica S, Scalzulli PR, Scarfo L, et al. The use of ibrutinib in Italian CLL patients treated in a real-world setting (EVIDENCE): a preliminary report. Blood. 2021;138(Supplement 1):4684. doi:10.1182/blood-2021-148378
   Google Scholar
• O’Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11. doi:10.3389/fonc.2021.720704
   Web of Science ®Google Scholar
• Dimou M, Iliakis T, Pardalis V, et al. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leuk Lymphoma. 2019;60(12):2939–2945. doi:10.1080/10428194.2019.1620944
   PubMed Web of Science ®Google Scholar
• Piernas Pontanilla S, Rámila Herrero E, De La Torre L S, et al. Valoración del tratamiento de la leucemia linfática crónica B con ibrutinib en términos de eficacia y tolerabilidad: experiencia en nuestro centro. SEHH-SETH. 2019.
   Google Scholar
• Ogunbiyi O, Arulogun SO, Patel A, et al. Real world experience on the use of ibrutinib monotherapy in waldenström macroglobulinemia. Blood. 2021;138(Supplement 1):4507. doi:10.1182/blood-2021-153714
   Google Scholar
• Dahlen T, Edgren G, Stenke L, et al. Overall survival and adverse events in 378 ibrutinib-treated patients with chronic lymphocytic leukemia - a Swedish register-based nationwide study. Blood. 2021;138(Supplement 1):3750. doi:10.1182/blood-2021-148537
   Google Scholar
• Garrido S, Montes A, Talegón M, et al. Eventos cardiovasculares (ECV) en pacientes con leucemia linfocítica crónica (LLC) tratados con inhibidores de tirosin-kinasa de bruton (BTK): características clínicas y manejo. SEHH-SETH. 2021. doi:10.3252/pso.es.63SEHH-37SETH.2021
   Google Scholar
• López García A, Peña Cortijo A, Pérez López C, et al. Experiencia en vida real con ibrutinib en diferentes indicaciones: perfil de efectos adversos en nuestro centro . SEHH-SETH. 2019.
   Google Scholar
• Kolacevic Zeljkovic M, Bulj N, Basic-Kinda S, et al. Comprehensive cardiac evaluation reveals no increase in ventricular arrhythmias in patients on chronic ibrutinib therapy – a study of KROHEM, the croatian cooperative group for hematologic diseases. EHA. 2021.
   Google Scholar
• Sverrisdottir I, Rögnvaldsson S, Lund S, et al. Multiple myeloma and comorbidity: a population-based study. EHA. 2017.
   Google Scholar
• Caldeira D, Alves D, Costa J, et al., Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019;14(2): e0211228. doi:10.1371/journal.pone.0211228.
   PubMed Web of Science ®Google Scholar
• García Bacelar A, Gomez García L, Bourgeois García M, et al. Tratamiento con ibrutinib y desarrollo de fa en pacientes oncohematológicos . SEHH-SETH. 2021. doi:10.3252/pso.es.63SEHH-37SETH.2021
   Google Scholar
• Leader A, ten Cate V, ten Cate-Hoek AJ, et al. Anticoagulation in thrombocytopenic patients with hematological malignancy: a multinational clinical vignette-based experiment. Eur J Intern Med. 2020;77:86–96.
   PubMed Web of Science ®Google Scholar
• Olivera Sumire P, Campoy Castaño D, Canals Pernas T, et al. Anticoagulantes orales directos vs. heparinas de bajo peso molecular en pacientes con fibrilación auricular y terapia antineoplásica activa. SEHH-SETH. 2019.
   Google Scholar
• Serrao A, Fiori L, Santoro C, et al. Direct oral anticoagulants in patients with hematologic malignancies. Hematol Oncol. 2020;38(4):589–596. doi:10.1002/hon.2770
   PubMed Web of Science ®Google Scholar
• Sapienza G. Ibrutinib and novel oral anticoagulants: three case reports from a single center real life experience. Blood. 2020;136(Supplement 1):37–38.
   Google Scholar
• EMA. Imbruvica: EPAR- product information [Internet]. 2019 [cited 2021 Mar 31; Accessed 2023 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf
   Google Scholar
• Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the International cardio-oncology society (IC-OS). Eur Heart J. 2022;43:4229–4361.
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. Study quality assessment tools [Internet]. 2021 cited 2023 May 10]. Available form 2023 May 10: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
   Google Scholar